New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Merck & Co., Inc.

MRK

Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.

Revenue
+4.68%
EPS
−12.1%
Free cash flow
−19.3%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

134.93 2.19 +1.65%
Market cap
$328.6B
P/E
137×
Fwd P/E FY26e
105×
Dividend yield
2.56%
F-score
4/9
ROIC
4.56%
Net debt / EBITDA
1.2×
Payout ratio
3.5×

Merck & Co., Inc. (MRK) Operating cash flow

Alert me on Operating cash flow

Merck & Co., Inc.'s operating cash flow for fiscal 2025 was $16.5B, down 23.3% from $21.5B in fiscal 2024. Over the twelve months to Sep 30, 2026 it was $18.7B. Over the past ten years it has ranged from $6.5B (fiscal 2017) to $21.5B (fiscal 2024); the current reading is higher than 82% of that period. Merck & Co., Inc. ranks 6th of 21 Drug Manufacturers General companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 $16.5B (23.27%)
FY2024 $21.5B 65.06%
FY2023 $13.0B (31.89%)
FY2022 $19.1B 45.52%
FY2021 $13.1B 72.27%
FY2020 $7.6B (14.26%)
FY2019 $8.9B (18.66%)
FY2018 $10.9B 69.31%
FY2017 $6.5B (37.83%)
FY2016 $10.4B (17.24%)

Quarterly newest first

Period Operating cash flow Change
Sep 2026 $6.6B 22.12%
Jun 2026 $5.4B 37.06%
Mar 2026 $3.9B 37.14%
Dec 2025 $2.9B (63.47%)
43 more quarters

Against its own ten years

Low $6.5B High $21.5B
Ten-year median $12.5B
Current reading's percentile 82

Operating cash flow against peers

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on MRK